Next Generation Sequencing
Support and Educational Content

Augmenting pathology data with molecular profiling for improved cancer treatment

In a remarkable, ongoing success story, Foundation Medicine, Inc (FMI) began a quest to bring the latest science and technology to routine cancer care, and in just a few years the company went public (NASDAQ: FMI) and grew to become one of the preeminent genomic profiling laboratories in the country. The company now provides 2 comprehensive genomic profiles for cancer (FoundationOne® for solid tumors, and FoundationOne® Heme for hematologic malignancies, sarcomas, and select pediatric cancers), and by the end of 2013 had tested over 10,000 patient samples. FMI partners with academic researchers, biopharmaceutical companies, and oncologists to refine the genomic information needed by for oncologists to make informed decisions about patient treatment.

At the 2014 AMP Meeting, FMI’s Research Director of Molecular Biology & Sequencing, Dr Geoff Otto, discussed FMI’s unique approach to assay development using targeted next-generation sequencing to generate molecular information that will better inform cancer categorization and treatment decisions. He described the challenges sample collection protocols create for genomic studies, and, using the example of a traditionally archived tissue specimen, illustrated how these results can complement FISH, IHC, and other data provided by the pathologist.

IDT has been collaborating with Foundation Medicine to provide pooled target capture probes (DNA baits) that ensure uniform coverage across the genomic loci that the FMI assays target.

Access the presentation here.

xGen® Blocking Oligos

Adapter blocking oligos increase the number of on-target reads by preventing non-specific binding during hybridization.

Find blockers for your platform ≫

Related Articles

Target Enrichment Facilitates Focused Next Generation Sequencing

The rationale and benefits of enriching subsets of the genome (target enrichment by hybrid capture) prior to sequencing.

Read more ≫

Improving Uniform Coverage of Targeted Sequences for NGS

The challenges faced in obtaining uniform coverage of NGS data and how IDT xGen® Lockdown® Probes are uniquely positioned to facilitate uniform sequence coverage.

Read more ≫

Towards Providing Personalized Medicine—Considerations for Reliable NGS Data

Geneseeq Technology, Inc. demonstrates how they improved their target capture methods to increase accuracy in clinical diagnostics by using optimized blocking oligos and stringent hybridization conditions.

Read more ≫

Delivering Comprehensive Genomic Profiling for Clinical Cancer Care Using Targeted Sequencing

Read how scientists at Foundation Medicine, Inc use hybrid selection in their FoundationOne® Test to help clinicians select patient specific treatment options.

Read more ≫

Insertion Site Detection and Targeted RNA Capture Using Next Generation Sequencing

Scientists at Cofactor Genomics use in-solution hybridization to focus on regions of interest for next generation sequencing.

Read more ≫